A lawsuit was filed on behalf of investors in Nektar Therapeutics (NASDAQ: NKTR) shares over alleged securities laws violations.

San Diego, CA -- (SBWire) -- 11/14/2018 --An investor, who purchased shares of Nektar Therapeutics (NASDAQ: NKTR), filed a lawsuit over alleged violations of Federal Securities Laws by Nektar Therapeutics in connection with certain allegedly false and misleading statements made.

Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and for certain investors are short and strict deadlines running. Deadline: December 31, 2018. NASDAQ: NKTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Francisco, CA based Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. NKTR-214, is the Company's lead immune-oncology ("I-O") candidate, is a biologic with biased signaling through one of the IL-2 receptor subunits (CD 122) that can stimulate proliferation and growth of tumor-killing immune cells in the tumor microenvironment and increase expression of PD-1 on these immune cells.

On October 1, 2018, Plainview LLC published a report raising questions about Nektar Therapeutics' claims concerning its clinical stage drug, NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer, and its ability to effectively treat cancer.

The plaintiff claims that between November 11, 2017, and October 2, 2018, the Defendants made false and/or misleading statements and/or failed to disclose that prior studies which attempted to pegylate IL-2 failed, that NKTR-214's extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns, that NKTR-214 was less effective than IL-2 alone, that the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results, and that as a result, Nektar's public statements as set forth above were materially false and misleading at all relevant times.

Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.